Pharma Journalist -

Longer-term use of the oral blood thinner Xarelto significantly cut the risk of recurrence of potentially life-threatening blood clots with no additional major bleeding compared with…
Read More...

Oxford BioDynamics is participating in a collaboration to identify the biological factors that trigger disease relapses, known as flares, in Rheumatoid Arthritis (RA), entitled the…
Read More...

Threshold Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing novel therapies for cancer, and Molecular Templates, Inc., a privately held biopharmaceutical…
Read More...

Acura Pharmaceuticals, Inc. and MainPointe Pharmaceuticals, LLC announced that they have entered into a License Agreement (the "Agreement") to have MainPointe exclusively market NEXAFED…
Read More...

Alkermes plc announced the initiation of a new phase 3 study of ALKS 8700, a novel, oral monomethyl fumarate (MMF) prodrug candidate in development for the treatment of relapsing forms…
Read More...

Israeli biotechnology company Kadimastem, announced that it has been granted a patent from the United States Patent and Trademark Office for its technology in the field of cell based…
Read More...

PTC Therapeutics, Inc. announced it has entered into an asset purchase agreement with Marathon Pharmaceuticals, LLC to acquire all rights to Emflaza™ (deflazacort). Emflaza is the first…
Read More...

Glycyx PharmaVentures Ltd., a biopharma investment and development company founded by Lorin K. Johnson, Ph.D., has agreed to enter into an exclusive license agreement with Valeant…
Read More...

Ferring Pharmaceuticals and Brazil-based Instituto de Ciências Farmacêuticas (ICF) today announced a research collaboration aimed at developing a mucoadhesive rectal delivery system to…
Read More...

Trovagene, Inc., a precision medicine biotechnology company, and Nerviano Medical Sciences, S.r.l., a leading oncology discovery organization, today announced that they have signed a…
Read More...